Considerations in the development of circulating tumor cell technology for clinical use

David R. Parkinson, Nicholas Dracopoli, Brenda G. Petty, Carolyn Compton, Massimo Cristofanilli, Albert Deisseroth, Daniel F. Hayes, Gordon Kapke, Prasanna Kumar, Jerry S H Lee, Minetta C. Liu, Robert McCormack, Stanislaw Mikulski, Larry Nagahara, Klaus Pantel, Sonia Pearson-White, Elizabeth A. Punnoose, Lori T. Roadcap, Andrew E. Schade, Howard I. ScherCaroline C. Sigman, Gary J. Kelloff

Research output: Contribution to journalArticle

223 Citations (Scopus)

Abstract

This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC) technologies for cancer patient diagnosis, prognosis, and response to therapy, as well as accelerating oncologic drug development. Moving forward requires the application of the classic steps in biomarker development-analytical and clinical validation and clinical qualification for specific contexts of use. To that end, this review describes methods for interactive comparisons of proprietary new technologies, clinical trial designs, a clinical validation qualification strategy, and an approach for effectively carrying out this work through a public-private partnership that includes test developers, drug developers, clinical trialists, the US Food & Drug Administration (FDA) and the US National Cancer Institute (NCI).

Original languageEnglish (US)
Article number138
JournalJournal of Translational Medicine
Volume10
Issue number1
DOIs
StatePublished - Jul 2 2012
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Tumors
Cells
Technology
Public-Private Sector Partnerships
Pharmaceutical Preparations
National Cancer Institute (U.S.)
Biomarkers
Clinical Trials
Food
Neoplasms
Therapeutics

Keywords

  • Analytical validation
  • Biomarker qualification
  • Circulating tumor cells
  • Clinical validation
  • Oncologic drug development
  • Predictive biomarker
  • Prognostic biomarker

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Parkinson, D. R., Dracopoli, N., Petty, B. G., Compton, C., Cristofanilli, M., Deisseroth, A., ... Kelloff, G. J. (2012). Considerations in the development of circulating tumor cell technology for clinical use. Journal of Translational Medicine, 10(1), [138]. https://doi.org/10.1186/1479-5876-10-138

Considerations in the development of circulating tumor cell technology for clinical use. / Parkinson, David R.; Dracopoli, Nicholas; Petty, Brenda G.; Compton, Carolyn; Cristofanilli, Massimo; Deisseroth, Albert; Hayes, Daniel F.; Kapke, Gordon; Kumar, Prasanna; Lee, Jerry S H; Liu, Minetta C.; McCormack, Robert; Mikulski, Stanislaw; Nagahara, Larry; Pantel, Klaus; Pearson-White, Sonia; Punnoose, Elizabeth A.; Roadcap, Lori T.; Schade, Andrew E.; Scher, Howard I.; Sigman, Caroline C.; Kelloff, Gary J.

In: Journal of Translational Medicine, Vol. 10, No. 1, 138, 02.07.2012.

Research output: Contribution to journalArticle

Parkinson, DR, Dracopoli, N, Petty, BG, Compton, C, Cristofanilli, M, Deisseroth, A, Hayes, DF, Kapke, G, Kumar, P, Lee, JSH, Liu, MC, McCormack, R, Mikulski, S, Nagahara, L, Pantel, K, Pearson-White, S, Punnoose, EA, Roadcap, LT, Schade, AE, Scher, HI, Sigman, CC & Kelloff, GJ 2012, 'Considerations in the development of circulating tumor cell technology for clinical use', Journal of Translational Medicine, vol. 10, no. 1, 138. https://doi.org/10.1186/1479-5876-10-138
Parkinson, David R. ; Dracopoli, Nicholas ; Petty, Brenda G. ; Compton, Carolyn ; Cristofanilli, Massimo ; Deisseroth, Albert ; Hayes, Daniel F. ; Kapke, Gordon ; Kumar, Prasanna ; Lee, Jerry S H ; Liu, Minetta C. ; McCormack, Robert ; Mikulski, Stanislaw ; Nagahara, Larry ; Pantel, Klaus ; Pearson-White, Sonia ; Punnoose, Elizabeth A. ; Roadcap, Lori T. ; Schade, Andrew E. ; Scher, Howard I. ; Sigman, Caroline C. ; Kelloff, Gary J. / Considerations in the development of circulating tumor cell technology for clinical use. In: Journal of Translational Medicine. 2012 ; Vol. 10, No. 1.
@article{babeb53dd1ca46668e6cae38824445ad,
title = "Considerations in the development of circulating tumor cell technology for clinical use",
abstract = "This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC) technologies for cancer patient diagnosis, prognosis, and response to therapy, as well as accelerating oncologic drug development. Moving forward requires the application of the classic steps in biomarker development-analytical and clinical validation and clinical qualification for specific contexts of use. To that end, this review describes methods for interactive comparisons of proprietary new technologies, clinical trial designs, a clinical validation qualification strategy, and an approach for effectively carrying out this work through a public-private partnership that includes test developers, drug developers, clinical trialists, the US Food & Drug Administration (FDA) and the US National Cancer Institute (NCI).",
keywords = "Analytical validation, Biomarker qualification, Circulating tumor cells, Clinical validation, Oncologic drug development, Predictive biomarker, Prognostic biomarker",
author = "Parkinson, {David R.} and Nicholas Dracopoli and Petty, {Brenda G.} and Carolyn Compton and Massimo Cristofanilli and Albert Deisseroth and Hayes, {Daniel F.} and Gordon Kapke and Prasanna Kumar and Lee, {Jerry S H} and Liu, {Minetta C.} and Robert McCormack and Stanislaw Mikulski and Larry Nagahara and Klaus Pantel and Sonia Pearson-White and Punnoose, {Elizabeth A.} and Roadcap, {Lori T.} and Schade, {Andrew E.} and Scher, {Howard I.} and Sigman, {Caroline C.} and Kelloff, {Gary J.}",
year = "2012",
month = "7",
day = "2",
doi = "10.1186/1479-5876-10-138",
language = "English (US)",
volume = "10",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Considerations in the development of circulating tumor cell technology for clinical use

AU - Parkinson, David R.

AU - Dracopoli, Nicholas

AU - Petty, Brenda G.

AU - Compton, Carolyn

AU - Cristofanilli, Massimo

AU - Deisseroth, Albert

AU - Hayes, Daniel F.

AU - Kapke, Gordon

AU - Kumar, Prasanna

AU - Lee, Jerry S H

AU - Liu, Minetta C.

AU - McCormack, Robert

AU - Mikulski, Stanislaw

AU - Nagahara, Larry

AU - Pantel, Klaus

AU - Pearson-White, Sonia

AU - Punnoose, Elizabeth A.

AU - Roadcap, Lori T.

AU - Schade, Andrew E.

AU - Scher, Howard I.

AU - Sigman, Caroline C.

AU - Kelloff, Gary J.

PY - 2012/7/2

Y1 - 2012/7/2

N2 - This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC) technologies for cancer patient diagnosis, prognosis, and response to therapy, as well as accelerating oncologic drug development. Moving forward requires the application of the classic steps in biomarker development-analytical and clinical validation and clinical qualification for specific contexts of use. To that end, this review describes methods for interactive comparisons of proprietary new technologies, clinical trial designs, a clinical validation qualification strategy, and an approach for effectively carrying out this work through a public-private partnership that includes test developers, drug developers, clinical trialists, the US Food & Drug Administration (FDA) and the US National Cancer Institute (NCI).

AB - This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC) technologies for cancer patient diagnosis, prognosis, and response to therapy, as well as accelerating oncologic drug development. Moving forward requires the application of the classic steps in biomarker development-analytical and clinical validation and clinical qualification for specific contexts of use. To that end, this review describes methods for interactive comparisons of proprietary new technologies, clinical trial designs, a clinical validation qualification strategy, and an approach for effectively carrying out this work through a public-private partnership that includes test developers, drug developers, clinical trialists, the US Food & Drug Administration (FDA) and the US National Cancer Institute (NCI).

KW - Analytical validation

KW - Biomarker qualification

KW - Circulating tumor cells

KW - Clinical validation

KW - Oncologic drug development

KW - Predictive biomarker

KW - Prognostic biomarker

UR - http://www.scopus.com/inward/record.url?scp=84863100828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863100828&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-10-138

DO - 10.1186/1479-5876-10-138

M3 - Article

C2 - 22747748

AN - SCOPUS:84863100828

VL - 10

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 138

ER -